Psychiatric NP Scope of Practice for Anxiety in Florida

If you’re a psychiatrist considering telehealth—or already practicing it—you’re navigating one of the most complex regulatory landscapes in medicine right now. Federal DEA rules, state licensing laws, and controlled substance regulations all intersect when you’re treating anxiety, ADHD, or other psychiatric conditions remotely. And if you prescribe benzodiazepines, stimulants, or any controlled medication via video visits, you need to know exactly what’s legal in each state where your patients are located.

The good news? As of 2025, federal telehealth flexibilities for controlled substance prescribing have been extended through December 31, 2025—meaning you can still evaluate new patients via telehealth and prescribe medications like Xanax or Adderall without requiring an initial in-person visit. The uncertainty? Those flexibilities are temporary, and the DEA is working on permanent rules that could reinstate stricter requirements.

This guide breaks down what you need to know as a psychiatrist practicing telehealth: the current federal rules, how state laws differ, and what it all means for your anxiety and ADHD patients who rely on remote care.

Federal DEA Rules: The Baseline for Controlled Substance Prescribing

The Ryan Haight Act and Its Exceptions

Under normal circumstances, federal law (the Ryan Haight Act, 21 U.S.C. §829(e)) prohibits prescribing controlled substances ‘by means of the Internet’ without a prior in-person medical evaluation. This was enacted in 2008 to prevent online pill mills, but it created a major barrier for legitimate telehealth psychiatry.

The law does outline exceptions—most notably during a public health emergency or when the practitioner is engaged in the ‘practice of telemedicine’ under specific conditions (like the patient being at a DEA-registered hospital during the teleconsult, or the prescriber having a special telemedicine DEA registration, which DEA has never fully implemented).

COVID-Era Flexibilities Extended Through 2025

When COVID-19 hit in March 2020, the DEA invoked the public health emergency exception, allowing controlled substance prescribing via telehealth without in-person exams for the first time on a widespread basis. This flexibility has now been extended three times—most recently in November 2024, when DEA and HHS announced the rules would remain in effect through December 31, 2025.

What this means for your practice today:

• You can evaluate a new anxiety patient via video and prescribe a benzodiazepine (like alprazolam for panic disorder) in that same visit—no in-person exam required
• You can initiate or continue stimulant medications for ADHD via telehealth
• This applies to Schedule II–V controlled substances, as long as you’re conducting an appropriate evaluation via live audiovisual telemedicine

The catch: These are temporary rules. In 2023, DEA proposed new regulations that would have reinstated an in-person visit requirement (with a limited 30-day tele-prescribing allowance). After 38,000+ public comments—many from mental health providers and patients—DEA postponed those rules and announced it’s working on a ‘new path forward for telemedicine.’ We’re all waiting to see what that looks like.

What Psychiatrists Should Do Now

Until DEA finalizes permanent rules:

• Stay informed: Subscribe to DEA updates and professional association alerts (APA, AAAP)
• Document thoroughly: Your telehealth encounters should be as detailed as in-person visits, noting the modality used and clinical decision-making
• Use video when possible: While audio-only may be allowed in limited cases, audiovisual evaluation is the clear standard for new controlled substance prescriptions
• Prepare for potential changes: Consider how you’d adapt if an in-person exam requirement returns—partnering with local clinics, hybrid care models, or limiting practice to certain medications

Free consultations available with select providers only.

Grow your practice on Klarity

Free to list. Pay only for new patient bookings. Most providers see their first patient within 24 hours.

Start seeing patients

Free to list. Pay only for new patient bookings. Most providers see their first patient within 24 hours.

State Licensing: You Must Be Licensed Where Your Patient Is Located

This is non-negotiable: you must hold a valid medical license in every state where your patients are located. Practicing medicine across state lines without proper licensure—even via telehealth—is illegal and can result in disciplinary action, fines, or criminal charges.

Interstate Medical Licensure Compact (IMLC)

The good news is that 40+ states now participate in the IMLC, which streamlines the process of obtaining licenses in multiple states. If you hold a full, unrestricted license in an IMLC member state as your ‘state of principal license,’ you can apply for expedited licensure in other member states.

Among our six priority states:

• IMLC members: Texas, Florida, Pennsylvania, Illinois
• Not in IMLC: California, New York

For California and New York—two of the largest markets for telepsychiatry—you’ll need to go through the standard licensing process. California in particular has no special telehealth license option; you need a full CA medical license to treat patients there, even if you never set foot in the state.

Bottom line: Multi-state telehealth practice requires multi-state licensure. Budget both time and money for this (application fees range from $500–$1,500+ per state, plus background checks and credential verification costs). Platforms like Klarity often assist providers with the licensing process to expand their geographic reach.

State-Specific Telehealth Prescribing Rules

While federal DEA policy sets the floor for controlled substance prescribing, each state overlays its own requirements—and they vary significantly. Here’s what you need to know for the six largest telehealth markets:

California: Telehealth-Friendly, But License-Strict

Telehealth evaluation standards: California does not require an in-person exam before prescribing via telehealth, as long as you conduct an ‘appropriate prior examination’ that meets the standard of care. California law (Business & Professions Code §2242) explicitly allows this exam to be done via telehealth—even asynchronously (questionnaires, etc.) if clinically appropriate, though synchronous video is always safer for psychiatric evaluation.

Controlled substances: No state-level prohibition on prescribing controlled substances via telehealth. You’re following federal DEA rules (currently, the extended flexibilities).

PDMP requirements: You must check the CURES database (California’s prescription monitoring program) when prescribing Schedule II–IV medications. Required at least every 4 months for ongoing therapy, and before the first prescription.

E-prescribing: Mandatory for all prescriptions as of 2022 (controlled and non-controlled).

Licensing: Full California medical license required—no shortcuts. Not in IMLC, so you apply directly through the California Medical Board (typically 3–6 months processing time).

PMHNP note: California is transitioning NPs to independent practice under AB 890. By 2026, experienced PMHNPs will be able to practice without physician oversight—increasing the pool of telehealth anxiety prescribers.

Texas: Video Required, Schedule II Limits for NPs

Telehealth standards: Texas mandates real-time audiovisual communication for establishing a new patient relationship. You can’t do an initial controlled substance evaluation via phone alone.

Controlled substance prescribing: Allowed via telehealth for mental health conditions (anxiety, ADHD, depression, etc.), except for treating chronic pain with Schedule II drugs—that requires in-person evaluation under Texas rules. For psychiatric care, this doesn’t apply; you can prescribe stimulants for ADHD or benzos for anxiety via video.

PDMP requirements: Texas mandates checking the Texas PMP before prescribing opioids, benzodiazepines, barbiturates, or carisoprodol. This became mandatory in 2019.

NP restrictions: Texas APRNs (including PMHNPs) cannot prescribe Schedule II controlled substances in outpatient settings except in hospitals or hospice. This means your PMHNP colleagues in Texas can prescribe benzodiazepines (Schedule IV) for anxiety but cannot prescribe Adderall for ADHD—only physicians can do that via telehealth in TX.

Licensing: Texas joined the IMLC in 2021, making multi-state licensing easier for qualified physicians.

Florida: Psychiatric Carve-Out for Schedule II

Telehealth regulations: Florida has explicit telehealth statutes (F.S. §456.47) requiring written patient consent for telehealth treatment. The standard of care still applies—you must conduct an appropriate evaluation.

Controlled substance exception: Florida prohibits prescribing Schedule II controlled substances via telehealth—with four exceptions: (1) treatment of a psychiatric disorder, (2) inpatient hospital care, (3) hospice, (4) nursing home residents. This psychiatric carve-out is crucial: you can prescribe Adderall for ADHD or other Schedule II medications for mental health conditions via telehealth in Florida.

PDMP requirements: Florida requires checking E-FORCSE (the state PDMP) before prescribing any Schedule II–V controlled substance, and at least every 90 days for ongoing therapy.

E-prescribing: Mandatory for controlled substances. Paper prescriptions require special tamper-proof pads.

Out-of-state providers: Florida offers a Telehealth Provider Registration that allows out-of-state psychiatrists to treat Florida patients without obtaining a full FL license—a relatively rare mechanism nationally. You must meet eligibility requirements (no discipline, malpractice insurance, etc.) and register with the Florida Department of Health.

PMHNP note: Florida NPs are classified as ‘psychiatric nurses’ if they have specific training/certification—allowing them to prescribe Schedule II for psychiatric conditions without the 7-day supply limit that applies to other NPs.

New York: Mandatory PDMP Checks and E-Prescribing

Telehealth standards: New York allows telehealth evaluations without requiring an in-person exam, as long as the standard of care is met. The state has been progressive in supporting tele-mental health, especially post-COVID.

I-STOP/PDMP: New York’s I-STOP law requires prescribers to check the state PMP before every Schedule II, III, or IV prescription—including benzodiazepines for anxiety. This is one of the strictest PDMP requirements in the country. Limited exceptions exist for emergencies or technical failures, but you must document attempts.

E-prescribing: New York was the first state to mandate e-prescribing for all medications (since March 2016). Very few exceptions apply.

NP independence: New York allows NPs with 3,600+ hours of practice to practice independently without a physician collaborative agreement (made permanent in 2022). This means experienced PMHNPs in NY can evaluate and prescribe for anxiety patients via telehealth under their own authority.

Licensing: Not in IMLC. You need a full NY medical license to treat patients there, which requires going through NY’s standard application process (typically 4–6 months).

Pennsylvania: PDMP Required for Every Benzo Prescription

Telehealth standards: Pennsylvania doesn’t have a comprehensive telehealth statute (though insurance parity was enacted in 2024). The state medical boards permit telemedicine if it meets the standard of care—real-time audiovisual is recommended for initial evaluations.

PDMP requirements: Pennsylvania’s Act 191 (enacted after the opioid crisis) requires PDMP checks before prescribing benzodiazepines and at each refill or new prescription. This makes PA one of the more stringent states for anxiety prescribers—every time you write for Xanax or Ativan, you need to check the database.

E-prescribing: Mandatory for controlled substances since 2019 (Act 96).

NP practice: Pennsylvania NPs must practice under a collaborative agreement with a physician. The agreement specifies prescriptive authority—typically Schedule II limited to 30-day supply, Schedule III–IV up to 90-day supply. Several bills proposing NP independence have been introduced but not enacted as of 2025.

Licensing: Pennsylvania joined the IMLC in 2017, facilitating multi-state licensure for physicians.

Illinois: Full NP Independence Available

Telehealth standards: Illinois is telehealth-friendly. No in-person exam requirement—just standard of care. Illinois law explicitly permits audio-only telehealth for mental health services if video isn’t available, though video is still preferred for controlled substance evaluations.

PDMP requirements: Illinois requires PDMP consultation for all Schedule II prescriptions and encourages it for all controlled substances. Most providers check for any controlled medication.

NP independence: Illinois offers Full Practice Authority (FPA) for APRNs with 4,000+ hours of experience and additional training. Once granted, NPs can prescribe controlled substances independently—though there’s a physician consultation requirement for Schedule II opioids during the first 5 years of FPA. For benzodiazepines (Schedule IV) and non-opioid Schedule IIs (like stimulants), FPA NPs can prescribe independently.

State controlled substance license: Illinois requires a separate state controlled substance license (in addition to DEA registration) for prescribing any controlled medication.

Licensing: Illinois joined the IMLC in 2018 (physicians) and the Nurse Licensure Compact in 2022 (RNs, though APRNs still need IL-specific authorization).

Common Compliance Requirements Across All States

Regardless of where you’re practicing:

1. DEA Registration

You must hold a valid DEA registration in the state where you’re practicing. If you’re licensed in multiple states, you need separate DEA registrations for each state where you’ll be prescribing.

2. Prescription Drug Monitoring Programs (PDMPs)

Every state now has a PDMP, and most mandate checking it before prescribing controlled substances. Requirements vary by state—some require checks before every prescription, others before the first prescription and periodically thereafter. Build this into your workflow; many EHR systems now integrate PDMP access.

3. E-Prescribing

The majority of states require or strongly encourage e-prescribing for controlled substances. California and New York mandate it for all prescriptions. You’ll need EPCS (Electronic Prescribing of Controlled Substances) capability with two-factor authentication.

4. Documentation Standards

Your telehealth documentation must meet the same standards as in-person care:

• Note the modality used (video, audio, etc.)
• Document the clinical exam (mental status exam, risk assessment, etc.)
• Include patient consent for telehealth treatment (required explicitly in Florida, Illinois, and considered best practice everywhere)
• Document PDMP checks and any prescribing decisions

5. Standard of Care

‘Telehealth’ doesn’t mean ‘lower standard.’ You’re expected to gather the same clinical information and make the same quality decisions as you would in person. If you can’t adequately assess a patient via video (e.g., they need a physical exam or lab work you can’t facilitate remotely), you must arrange for that care.

Economics of Telehealth Practice: Why Platforms Like Klarity Make Sense

Let’s talk about the business reality. Setting up your own multi-state telehealth practice sounds appealing—full control, direct patient relationships—but the economics are challenging:

What it actually costs to acquire psychiatric patients independently:

• SEO: 6–12 months of consistent investment ($2,000–5,000/month for content, backlinks, technical optimization) before generating meaningful patient flow. You’re competing with established platforms and directories.

• Google Ads: Mental health keywords cost $15–40+ per click. Conversion rates are low (most clicks don’t book). Realistic cost per booked patient: $200–400+ when you factor in testing, optimization, and staff time to qualify leads.

• Directory listings (Psychology Today, Zocdoc): Monthly subscription fees plus per-booking charges. Zocdoc charges $35–100+ per booking, but you’re competing with hundreds of providers on the same platform. Total monthly cost adds up quickly.

• No-show rates: Cold leads from ads or directories have higher no-show rates than platform-matched patients, increasing your effective acquisition cost.

• Multi-state licensing: Budget $3,000–10,000+ just to get licensed in 4–5 states (application fees, background checks, time spent on paperwork).

• Compliance infrastructure: PDMP access in multiple states, EPCS software, malpractice insurance for telehealth, EHR with multi-state capability—these aren’t free.

Total reality check: Most solo practitioners spend $3,000–5,000/month on marketing with uncertain results, plus significant time managing leads, scheduling, and compliance.

How Klarity Health’s model compares:

Instead of gambling on marketing channels with uncertain ROI, Klarity uses a pay-per-appointment model:

• No upfront marketing spend or monthly subscription fees
• Pre-qualified patients already matched to your specialty, availability, and insurance
• No wasted ad spend on clicks that don’t convert—you only pay when a patient books with you
• Built-in telehealth infrastructure—no separate platform costs for video, e-prescribing, or EHR
• Both insurance and cash-pay patient flow
• Multi-state licensing support—Klarity helps facilitate the licensing process
• You control your schedule—set your availability, accept patients that fit your practice

The business case: rather than spending thousands monthly on marketing with uncertain results, you pay a standard listing fee per qualified patient lead. That’s guaranteed ROI versus gambling on SEO or PPC that may never generate patients.

For psychiatrists, especially those scaling a practice or adding telehealth, this removes the risk entirely. You can focus on clinical care while the platform handles patient acquisition, compliance infrastructure, and administrative overhead.

What’s Coming: Preparing for Post-2025 DEA Rules

The current telehealth prescribing flexibilities expire December 31, 2025. While DEA and HHS could extend them again, it’s more likely we’ll see new permanent rules sometime in 2025 or 2026.

Possible scenarios:

1. Hybrid requirement: Initial telehealth prescription allowed (maybe 30-day supply), but in-person exam required to continue long-term controlled substance therapy

2. Special telemedicine DEA registration: DEA finally implements the registration mechanism outlined in the Ryan Haight Act, allowing qualified practitioners to prescribe controlled substances via telehealth without in-person exams

3. State-specific exceptions: Federal rules might defer more to state law, creating even more variation

4. Permanent flexibilities for psychiatric care: Recognition that mental health prescribing (especially for anxiety and ADHD) is fundamentally different from pain management and should have different rules

How to prepare:

• Build relationships with local clinics or practices in states where you have high patient volume—this could facilitate in-person exams if required
• Consider hybrid models: Video for most care, but establish pathways for patients to see someone in person when needed
• Advocate: Join professional organizations (APA, AAAP) that are lobbying for sensible telehealth rules
• Stay flexible: The regulatory landscape is evolving; providers who can adapt quickly will maintain access to patients

Bottom Line: Telehealth Is Here to Stay—But the Rules Keep Changing

Telehealth transformed psychiatric care during COVID-19, and patients—especially those with anxiety and ADHD—have come to rely on remote access to medication management. As of February 2025, the regulatory environment supports this: you can evaluate patients via video and prescribe controlled substances without an in-person visit.

But this is a temporary regulatory state. The smartest psychiatrists are:

1. Staying compliant with current federal and state rules (DEA flexibilities, state PDMP requirements, licensure in patient states)
2. Documenting meticulously to demonstrate standard-of-care telehealth practice
3. Preparing for change by building flexibility into their practice models
4. Focusing on clinical care rather than spending months and thousands of dollars trying to DIY patient acquisition

If you’re a psychiatrist looking to expand your telehealth practice—or start one—platforms like Klarity Health remove the regulatory complexity and financial risk. You get matched with pre-qualified patients, compliance infrastructure is built in, and you control your schedule. It’s the difference between spending $5,000/month on marketing that might not work versus paying only when a qualified patient books with you.

Ready to explore how Klarity can help you scale your telehealth practice without the marketing gamble? Join our provider network and get connected with patients in the states where you’re licensed—on your schedule, with the compliance support you need.

Sources & Citations

1. DEA & HHS Telemedicine Extension Announcement (November 15, 2024)
   ‘DEA and HHS Extend Telemedicine Flexibilities through 2025’
   https://www.dea.gov/documents/2024/2024-11/2024-11-15/dea-and-hhs-extend-telemedicine-flexibilities-through-2025
   Official DEA policy extending COVID-era telehealth prescribing rules through December 31, 2025

2. 21 U.S.C. § 829(e) – Ryan Haight Online Pharmacy Consumer Protection Act
   Cornell Law School Legal Information Institute
   https://www.law.cornell.edu/uscode/text/21/829
   Federal statute governing controlled substance prescribing via the Internet

3. Center for Connected Health Policy – State Telehealth Policies: Online Prescribing
   Updated January 9, 2026
   https://www.cchpca.org/topic/online-prescribing/
   Comprehensive state-by-state analysis of telehealth prescribing laws with official citations

4. Florida Statutes § 456.47 – Telehealth Services
   2025 Edition (through 2024 legislative session)
   http://www.leg.state.fl.us/Statutes/
   Florida’s telehealth law including Schedule II prescribing exceptions for psychiatric treatment

5. New York Department of Health – I-STOP/Prescription Monitoring Program
   Effective August 27, 2013 (accessed 2025)
   https://health.ny.gov/professionals/narcotic/prescription_monitoring
   New York’s mandatory PDMP consultation requirements for Schedule II-IV prescriptions

Source:

• https://www.dea.gov/documents/2024/2024-11/2024-11-15/dea-and-hhs-extend-telemedicine-flexibilities-through-2025#:~:text=forward%20for%20telemedicine%2C%20DEA%20and,through%20the%20end%20of%202024
• https://www.cchpca.org/topic/online-prescribing/#:~:text=Controlled%20Substance%20Act
• https://www.cchpca.org/topic/online-prescribing/#:~:text=Note%20that%20the%20practice%20of,chapter%205%20of%20title%205
• https://www.flsenate.gov/Laws/Statutes/2025/456.47#:~:text=,services%20within%20the%20applicable%20scope
• https://healthweb-back.health.ny.gov/professionals/narcotic/prescription_monitoring/#:~:text=Effective%20August%2027%2C%202013%2C%20most,to%20view%20dispensed%20controlled%20substance
• https://www.bon.texas.gov/faqpracticeaprn.asp.html#:~:text=may%20prescribe%20Schedule%20II%20drugs%3F,care%20from%20a%20qualified%20hospice
• https://www.leg.state.fl.us/Statutes/index.cfm?Appmode=DisplayStatute&Search_String=&URL=0400-0499%2F0464%2FSections%2F0464.012.html#:~:text=893.03%20to%20a%207,formulary%20which%20it%20finds%20is
• https://www.flsenate.gov/Laws/Statutes/2025/456.47#:~:text=,is%20prescribed%20for%20the%20following
• https://www.cchpca.org/topic/online-prescribing/#:~:text=Additionally%2C%20the%20rule%20shall%20state,addiction%20medicine%2C%20or%20palliative%20care
• https://www.cchpca.org/topic/online-prescribing/#:~:text=The%20Attorney%20General%20may%20issue,application%20for%20such%20special%20registration%E2%80%94